Multicenter US clinical experience with the Scepter Mini balloon catheter
Mohamed M Salem,Paz Kelmer,Georgios S Sioutas,Sophie Ostmeier,Alex Hoang,Gustavo Cortez,Kareem El Naamani,Rawad Abbas,Ricardo Hanel,Omar Tanweer,Visish M Srinivasan,Pascal Jabbour,Peter Kan,Brian T Jankowitz,Jeremy J Heit,Jan-Karl Burkhardt,Mohamed M. Salem,Georgios S. Sioutas,Visish M. Srinivasan,Brian T. Jankowitz,Jeremy J. Heit
DOI: https://doi.org/10.1177/15910199241246135
IF: 1.7
2024-04-14
Interventional Neuroradiology
Abstract:Interventional Neuroradiology, Ahead of Print. IntroductionDistal navigability and imprecise delivery of embolic agents are two limitations encountered during liquid embolization of cerebrospinal lesions. The dual-lumen Scepter Mini balloon (SMB) microcatheter was introduced to overcome these conventional microcatheters' limitations with few small single-center reports suggesting favorable results.MethodsA series of consecutive patients undergoing SMB-assisted endovascular embolization were extracted from prospectively maintained registries in seven North-American centers (November 2019 to September 2022).ResultsFifty-four patients undergoing 55 embolization procedures utilizing SMB were included (median age 58.5; 48.1% females). Cranial dural arteriovenous fistula embolization was the most common indication (54.5%) followed by cranial arteriovenous malformation (27.3%). Staged/pre-operative embolization was done in 36.4% of cases; and 83.6% of procedures using Onyx-18. Most procedures utilized a transarterial approach (89.1%), and SMB-induced arterial-flow arrest concurrently with transvenous embolization was used in 10.9% of procedures. Femoral access/triaxial setups were utilized in the majority of procedures (65.5% and 60%, respectively). The median vessel diameter where the balloon was inflated of 1.8 mm, with a median of 1.5 cc of injected embolic material per procedure. Technical failures occurred in 5.5% of cases requiring aborting/replacement with other devices without clinical sequelae in any of the patients, with SMB-related procedural complications of 3.6% without clinical sequelae. Radiographic imaging follow-up was available in 76.9% of the patients (median follow-up 3.8 months), with complete occlusion (100%) or >50% occlusion in 92.5% of the cases, and unplanned retreatments in 1.8%.ConclusionThe SMB microcatheter is a useful new adjunctive device for balloon-assisted embolization of cerebrospinal lesions with a high technical success rate, favorable outcomes, and a reasonable safety profile.
radiology, nuclear medicine & medical imaging,clinical neurology